Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | PI4KA | P42356 | 4/20 | 0.65 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.65 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | APEX1 | P27695 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29683060 | 1.00 | CYP2C19 (0.68) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| Methane SCHEMBL10552077 | 0.99 | CYP2C19 (0.67) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1998927 | 0.96 | PI4KA (0.71) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| Methane SCHEMBL10551641 | 0.94 | PI4KA (0.69) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| Ether SCHEMBL10547204 | 0.91 | CYP2C19 (0.61) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4572213 | 0.84 | CYP2C19 (0.74) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL31569297 | 0.84 | CYP2C19 (0.74) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL3643112 | 0.84 | CYP2C19 (0.56) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1324553 | 0.83 | CYP2C19 (0.72) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL219612 | 0.83 | CYP2C19 (0.68) | CYP2C19PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 525 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244452-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC (US) | 2016-08-25 | — | — | US | claimed |
| WO-2015061204-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2015-04-30 | — | — | WO | claimed |
| US-20260117148-A1 | SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE | FUJIFILM CORP (JP) | 2026-04-30 | — | — | US | disclosed |
| US-20260042780-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250353857-A1 | COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1 R) | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2025-11-20 | — | — | US | disclosed |
| US-20250340565-A1 | CD73 INHIBITOR COMPOUNDS | ADORX THERAPEUTICS LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| US-20250320430-A1 | SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE | FUJIFILM CORP (JP) | 2025-10-16 | — | — | US | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| EP-3719018-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2025-08-27 | — | — | EP | disclosed |
| EP-4594308-A1 | N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF | Vividion Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025134877-A1 | KIT AND METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE | FUJIFILM CORPORATION (JP) | 2025-06-26 | — | — | WO | disclosed |
| US-5164390-A | Cardiac disorders | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0458618-A1 | 6-Substituted purinyl piperazine derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-11-27 | — | — | EP | disclosed |
| US-5021574-A | Cardiotonic agents, antiarrhythmia agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-06-04 | — | — | US | disclosed |
| EP-0212535-B1 | N6-DISUBSTITUTED PURINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1991-05-29 | — | — | EP | disclosed |
| US-4876257-A | 6-Substituted purinyl piperazine derivatives useful as cardiotonic and antiarrhythmic agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-10-24 | — | — | US | disclosed |
| EP-0331511-A1 | 6-Substituted purinyl piperazine derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-09-06 | — | — | EP | disclosed |
| US-4853386-A | INHIBITORS OF SRS-A(SLOW REACTING SUBSTANCE OF ANAPHYLAXIS) FROM LUNG TISSUES | BOEHRINGER MANNHEIM GMBH (DE) | 1989-08-01 | — | — | US | disclosed |
| EP-0212535-A1 | N6-disubstituted purine derivatives, process for their preparation and medicaments containing them | Roche Diagnostics GmbH (DE) | 1987-03-04 | — | — | EP | disclosed |
| US-4241063-A | Purine derivatives and their use as bronchodilators | BRISTOL-MYERS COMPANY (US) | 1980-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244452-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CYP2C19 1354/4885PI4KA 14/4885PI4K2B 32/4885 |
| US-20260117148-A1 | SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE | TPMT, P2RY13, TST | CYP2C19 1995/4885PI4KA 2806/4885PI4K2B 3216/4885 |
| US-20250340565-A1 | CD73 INHIBITOR COMPOUNDS | ENTPD5, ENTPD1, NT5E | CYP2C19 653/4885PI4KA 2088/4885PI4K2B 2888/4885 |
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | CYP2C19 1292/4885PI4KA 409/4885PI4K2B 621/4885 |
| US-20250353857-A1 | COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1 R) | CSF1R, CSF3R, IL1RN | CYP2C19 4612/4885PI4KA 1750/4885PI4K2B 1785/4885 |
| US-20260042780-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PTEN, PIK3C2A, PIK3CA | CYP2C19 845/4885PI4KA 41/4885PI4K2B 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.